• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cerevel Therapeutics Shares Trading Higher Amid Circulation Of Rumors That The FTC Closed Door Meeting May Be About The Co's Merger With Tempur Sealy International

    6/27/24 3:53:09 PM ET
    $CERE
    $TPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Home Furnishings
    Consumer Discretionary
    Get the next $CERE alert in real time by email
    Cerevel Therapeutics Shares Trading Higher Amid Circulation Of Rumors That The FTC Closed Door Meeting May Be About The Co's Merger With Tempur Sealy International
    Get the next $CERE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERE
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    Tempur Sealy International Inc.
    $TPX
    2/5/2025Mkt Perform → Outperform
    William Blair
    Tempur Sealy International Inc.
    $TPX
    2/3/2025$67.00 → $80.00Neutral → Outperform
    Wedbush
    Tempur Sealy International Inc.
    $TPX
    9/4/2024$52.00Outperform → Neutral
    Wedbush
    Tempur Sealy International Inc.
    $TPX
    3/25/2024$50.00 → $75.00Hold → Buy
    Loop Capital
    Tempur Sealy International Inc.
    $TPX
    1/18/2024$41.00 → $61.00Neutral → Overweight
    Piper Sandler
    Cerevel Therapeutics Holdings Inc.
    $CERE
    12/8/2023$45.00Outperform → Market Perform
    TD Cowen
    Cerevel Therapeutics Holdings Inc.
    $CERE
    11/20/2023$25.00Neutral
    JP Morgan
    Cerevel Therapeutics Holdings Inc.
    $CERE
    9/28/2023$33.00Overweight
    Piper Sandler
    More analyst ratings

    $CERE
    $TPX
    SEC Filings

    View All

    Tempur Sealy International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SOMNIGROUP INTERNATIONAL INC. (0001206264) (Filer)

    2/20/25 6:40:59 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - SOMNIGROUP INTERNATIONAL INC. (0001206264) (Filer)

    2/20/25 6:39:52 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy International Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - SOMNIGROUP INTERNATIONAL INC. (0001206264) (Filer)

    2/18/25 4:41:30 PM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    $CERE
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempur Sealy Completes Name Change to Somnigroup International

    LEXINGTON, Ky., Feb. 18, 2025 /PRNewswire/ -- Somnigroup International Inc. (NYSE:SGI, ", Company", or ", Somnigroup", )), formerly Tempur Sealy International, today announced the completion of its name change. Shares of Somnigroup common stock trade on the New York Stock Exchange under the ticker symbol "SGI." Scott Thompson, Somnigroup Chairman and CEO said, "Somnigroup is the world's largest bedding company, with superior capabilities in design, manufacturing, distribution and retail while owning a portfolio of the most highly recognized brands in the industry. The name Somnigroup is derived from the Latin words "somn," meaning sleep, "omni," meaning all, and "group" to reflect our posit

    2/18/25 6:55:00 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Leadership Change at Mattress Firm

    -  New Interim CEO of Mattress Firm, Scott Thompson LEXINGTON, Ky., Feb. 12, 2025 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )) today announced management changes at Mattress Firm. The Company recently acquired Mattress Firm, the nation's largest mattress specialty retailer. John Eck has decided to step down as Chief Executive Officer of Mattress Firm.  The Company has entered into a consulting agreement with Mr. Eck to ensure a smooth transition. Scott Thompson, Chairman and CEO of Tempur Sealy, will act as Interim CEO of Mattress Firm during a transition period. The Company expects to appoint a new CEO of Mattress Firm within the next 6 t

    2/12/25 9:00:00 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    $CERE
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempur Sealy Int'l upgraded by William Blair

    William Blair upgraded Tempur Sealy Int'l from Mkt Perform to Outperform

    2/5/25 8:03:48 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy Int'l upgraded by Wedbush with a new price target

    Wedbush upgraded Tempur Sealy Int'l from Neutral to Outperform and set a new price target of $80.00 from $67.00 previously

    2/3/25 8:34:04 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy Int'l downgraded by Wedbush with a new price target

    Wedbush downgraded Tempur Sealy Int'l from Outperform to Neutral and set a new price target of $52.00

    9/4/24 8:22:21 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    $CERE
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachse Peter R was granted 120,953 shares (SEC Form 4)

    4 - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Issuer)

    2/7/25 4:17:40 PM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    SEC Form 3 filed by new insider Sachse Peter R

    3 - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Issuer)

    2/7/25 4:16:20 PM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    EVP, CMO U.S. Murray Thomas A. converted options into 29,228 shares and covered exercise/tax liability with 11,655 shares, increasing direct ownership by 10% to 195,892 units (SEC Form 4)

    4 - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Issuer)

    1/6/25 4:19:11 PM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    $CERE
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Koppel Adam bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

    4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

    10/18/23 4:30:12 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gordon Christopher R bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

    4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

    10/18/23 4:30:16 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bain Capital Investors Llc bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

    4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)

    10/18/23 4:30:09 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CERE
    $TPX
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward." "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver. Ms.

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Home Furnishings

    Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

    Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie

    6/15/23 6:30:00 AM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CERE
    $TPX
    Financials

    Live finance-specific insights

    View All

    Tempur Sealy Successfully Completes Acquisition of Mattress Firm

    -  Announces Tempur Sealy International, Inc to Change its Name to Somnigroup International Inc., Reflecting Acceleration of Omni-Channel Strategy-  Hosting Business Update Call on February 6, 2025 LEXINGTON, Ky., Feb. 5, 2025 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )) today announced that it has completed its previously announced acquisition of Mattress Firm Group Inc. ("Mattress Firm"), the nation's largest mattress specialty retailer. In a separate release today, the Company announced it will change its name to Somnigroup International Inc. ("Somnigroup"), effective February 18, 2025. Mattress Firm, Dreams and Tempur Sealy will operat

    2/5/25 9:51:00 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy Cleared to Close Acquisition of Mattress Firm

    LEXINGTON, Ky., Feb. 4, 2025 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", )) announced today that it expects to close its previously announced acquisition of Mattress Firm Group Inc. ("Mattress Firm"), the nation's largest mattress specialty retailer, on Wednesday, February 5, 2025. This follows the ruling from the United States District Court for the Southern District of Texas denying the motion by the Federal Trade Commission ("FTC") for a preliminary injunction to halt the closing of the proposed acquisition. The FTC has indicated that it will not seek emergency relief from the Fifth Circuit and will not prevent the transaction from closing

    2/4/25 12:10:00 PM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    Tempur Sealy International to Report Fourth Quarter and Full Year 2024 Financial Results

    LEXINGTON, Ky., Jan. 15, 2025 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) will release its financial results for the fourth quarter and full year ended December 31, 2024, before the NYSE opening of regular trading on Thursday, February 20, 2025. The Company will hold a conference call at 8:00 a.m. Eastern Time. The call will be webcast and can be accessed on the Company's investor relations website at investor.tempursealy.com. After the conference call, a webcast replay will remain available on the website for 30 days. About the Company Tempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, dis

    1/15/25 6:55:00 AM ET
    $TPX
    Home Furnishings
    Consumer Discretionary

    $CERE
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

    SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

    8/5/24 6:12:07 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

    SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

    8/5/24 4:30:55 PM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

    SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)

    5/10/24 10:03:20 AM ET
    $CERE
    Biotechnology: Pharmaceutical Preparations
    Health Care